Richard T Crowder Net Worth

The estimated Net Worth of Richard T Crowder is at least $438 Mille dollars as of 19 May 2016. Richard Crowder owns over 27,250 units of Neogen stock worth over $438,438 and over the last 14 years Richard sold NEOG stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Richard Crowder NEOG stock SEC Form 4 insiders trading

Richard has made over 4 trades of the Neogen stock since 2010, according to the Form 4 filled with the SEC. Most recently Richard exercised 27,250 units of NEOG stock worth $617,485 on 19 May 2016.

The largest trade Richard's ever made was exercising 27,250 units of Neogen stock on 19 May 2016 worth over $617,485. On average, Richard trades about 5,550 units every 206 days since 2010. As of 19 May 2016 Richard still owns at least 28,750 units of Neogen stock.

You can see the complete history of Richard Crowder stock trades at the bottom of the page.

What's Richard Crowder's mailing address?

Richard's mailing address filed with the SEC is , , , , .

Insiders trading at Neogen

Over the last 24 years, insiders at Neogen have traded over $135,917,555 worth of Neogen stock and bought 195,554 units worth $4,379,833 . The most active insiders traders include James L Herbert, Jeffrey D Capello e Lon M Bohannon. On average, Neogen executives and independent directors trade stock every 11 days with the average trade being worth of $140,346. The most recent stock trade was executed by Ronald D Green on 29 August 2024, trading 4,446 units of NEOG stock currently worth $68,780.

What does Neogen do?

neogen corporation develops and markets products dedicated to food and animal safety. the company’s food safety division markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. neogen’s animal safety division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants and rodenticides.

Complete history of Richard Crowder stock trades at Neogen

Neogen executives and stock owners

Neogen executives and other stock owners filed with the SEC include:

• John Adent,
  President, Chief Executive Officer, Director
• Steven Quinlan,
  Chief Financial Officer, Vice President, Secretary
• John Edward Adent,
  Pres, CEO & Director
• Jason Lilly,
  Vice President - International Business
• Jerome Hagedorn,
  Vice President - Food Safety operations
• Douglas E. Jones,
  VP & Chief Commercial Officer
• Steven J. Quinlan,
  VP & CFO
• James Borel,
  Lead Independent Chairman of the Board
• James Tobin,
  Independent Director
• Ronald Green,
  Independent Director
• William Boehm,
  Independent Director
• Darci Vetter,
  Independent Director
• G. Bruce Papesh,
  Independent Director
• Doug Jones,
  Chief Commercial Officer
• Amy M. Rocklin Ph.D.,
  VP, Gen. Counsel & Corp. Sec.
• Julie A. Mann,
  VP & Chief HR Officer
• Rod Poland,
  Director of Corp. Communications
• Amy Rocklin Ph.D.,
  VP & Gen. Counsel
• Sarah Demey,
  Admin. Mang.
• Bruce Papesh,
  Director
• A Charles Fischer,
  Director
• Richard E Jr Calk,
  President & COO
• Richard T Crowder,
  Director
• Jack C Parnell,
  Director
• Clayton K Yeutter,
  Director
• Thomas H Reed,
  Director
• Terri A Morrical,
  
• David H. Naemura,
  Chief Financial Officer
• Edward Bradley,
  V.P. Sales and Marketing
• Aashima Gupta,
  Director
• Jeffrey D Capello,
  Director
• Rex L Hamilton,
  Vice President
• Herbert D Doan,
  Director
• Gordon E Guyer,
  Director
• James L Herbert,
  Director
• Joseph M Madden,
  V.P. Scientific Affairs
• Richard R Current,
  Vice President & CFO
• Anthony E Maltese,
  VP Business Development
• Kenneth V Kodilla,
  Vice President
• Lon M Bohannon,
  COO
• Mark A Mozola,
  Vice President of R&D
• Leonard E Heller,
  Director
• Robert M Book,
  Director
• Stephen K. Snyder,
  Former Pres. and COO
• Paul S Satoh,
  V.P Research and Development
• Rafael A Rodriguez,
  Director
• Catherine E Woteki,
  Director
• Amy M Rocklin,
  Chief Legal Officer
• John Patrick Moylan,
  Chief Accounting Officer